S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs

CONMED Stock Price, News & Analysis (NYSE:CNMD)

$109.62
+2.35 (+2.19%)
(As of 12/1/2023 ET)
Compare
Today's Range
$106.93
$109.92
50-Day Range
$91.30
$109.62
52-Week Range
$82.97
$138.47
Volume
225,600 shs
Average Volume
376,914 shs
Market Capitalization
$3.37 billion
P/E Ratio
59.25
Dividend Yield
0.73%
Price Target
$126.17

CONMED MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
15.1% Upside
$126.17 Price Target
Short Interest
Bearish
15.35% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
-0.25mentions of CONMED in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$337,488 Sold Last Quarter
Proj. Earnings Growth
26.29%
From $3.50 to $4.42 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

417th out of 950 stocks

Electromedical Equipment Industry

7th out of 21 stocks


CNMD stock logo

About CONMED Stock (NYSE:CNMD)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CNMD Stock Price History

CNMD Stock News Headlines

Analyzing CONMED (NYSE:CNMD) and NeurAxis (NASDAQ:NRXS)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
The Conmed Corp (CNMD) Company: A Short SWOT Analysis
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
CNMD or ALGN: Which Is the Better Value Stock Right Now?
Conmed Corp. Q3 Profit Decreases, but beats estimates
Conmed: Q3 Earnings Snapshot
Conmed Corp (CNMD) Announces Q3 2023 Financial Results
See More Headlines
Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/5 Dividend
9/14/2023
Dividend Payable
10/05/2023
Last Earnings
10/25/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/01/2024

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Employees
4,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$126.17
High Stock Price Target
$141.00
Low Stock Price Target
$107.00
Potential Upside/Downside
+15.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-80,580,000.00
Pretax Margin
2.53%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$5.39 per share
Book Value
$25.89 per share

Miscellaneous

Free Float
28,415,000
Market Cap
$3.37 billion
Optionable
Optionable
Beta
1.37
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














CNMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CONMED stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNMD shares.
View CNMD analyst ratings
or view top-rated stocks.

What is CONMED's stock price target for 2024?

6 Wall Street analysts have issued twelve-month price targets for CONMED's shares. Their CNMD share price targets range from $107.00 to $141.00. On average, they predict the company's stock price to reach $126.17 in the next year. This suggests a possible upside of 15.1% from the stock's current price.
View analysts price targets for CNMD
or view top-rated stocks among Wall Street analysts.

How have CNMD shares performed in 2023?

CONMED's stock was trading at $88.64 at the start of the year. Since then, CNMD shares have increased by 23.7% and is now trading at $109.62.
View the best growth stocks for 2023 here
.

Are investors shorting CONMED?

CONMED saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,720,000 shares, an increase of 7.8% from the October 31st total of 4,380,000 shares. Based on an average trading volume of 359,400 shares, the short-interest ratio is presently 13.1 days.
View CONMED's Short Interest
.

When is CONMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our CNMD earnings forecast
.

How were CONMED's earnings last quarter?

CONMED Co. (NYSE:CNMD) announced its quarterly earnings results on Wednesday, October, 25th. The company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.07. The firm earned $304.58 million during the quarter, compared to the consensus estimate of $301.22 million. CONMED had a net margin of 4.96% and a trailing twelve-month return on equity of 11.46%.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Thursday, August 10th. Investors of record on Friday, September 15th will be paid a dividend of $0.20 per share on Thursday, October 5th. This represents a $0.80 annualized dividend and a dividend yield of 0.73%. The ex-dividend date is Thursday, September 14th.
Read our dividend analysis for CNMD
.

Is CONMED a good dividend stock?

CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.75%. The dividend payout ratio is 43.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNMD will have a dividend payout ratio of 18.10% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CNMD.

What guidance has CONMED issued on next quarter's earnings?

CONMED updated its FY23 earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $3.45-3.55 for the period, compared to the consensus EPS estimate of $3.48. The company issued revenue guidance of $1.24-1.26 billion, compared to the consensus revenue estimate of $1.25 billion.

Who are CONMED's major shareholders?

CONMED's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Earnest Partners LLC (7.37%), Loomis Sayles & Co. L P (2.57%), Principal Financial Group Inc. (1.99%), Bank of New York Mellon Corp (1.39%), Jennison Associates LLC (1.19%) and Northern Trust Corp (1.10%). Insiders that own company stock include Brian Concannon, Curt R Hartman, Daniel S Jonas, John D Ferrell, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Todd W Garner and Todd W Garner.
View institutional ownership trends
.

How do I buy shares of CONMED?

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:CNMD) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -